Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pixatimod and Nivolumab With or Without Cyclophosphamide in Advanced Solid Tumors
NCT05061017Phase 2Completed
- Start
- Dec 2021
- Primary completion
- Feb 2024
- Modality
- Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
A Phase 2 trial of pixatimod in melanoma, non-small cell lung cancer (NSCLC), colorectal carcinoma (CRC). Started Dec 2021; status: completed.
02
Drugs
pixatimod
03
Conditions
melanomanon-small cell lung cancer (NSCLC)colorectal carcinoma (CRC)
Beyond the preview
Go deeper on NCT05061017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05061017.